Pimavanserin

Key Product Details

Product Description

Pimavanserin (also known as ACP-103) is a selective, potent 5-HT_2A receptor inverse agonist (IC₅₀ = 2 nM). Pimavanserin displays ~ 40-fold higher affinity for 5-HT_2A over 5-HT_2C receptor. Chronic administration of Pimavanserin, suppresses amyloid-β production and improves anxiety-related behavior and memory in Alzheimer's disease mouse models. Pimavanserin shows protective effects on midbrain dopaminergic neurons in a rat model of Parkinson's Disease.

Product Specifications for Pimavanserin

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Pimavanserin

The following data is based on the product molecular weight 427.56.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.34 mL	11.69 mL	23.39 mL
5 mM	0.47 mL	2.34 mL	4.68 mL
10 mM	0.23 mL	1.17 mL	2.34 mL
50 mM	0.05 mL	0.23 mL	0.47 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Vanover Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J.Pharmacol.Exp.Ther. 2006 PMID: 16469866
• Yuede Pimavanserin, a 5HT 2A receptor inverse agonist, rapidly suppresses A beta production and related pathology in a mouse model of Alzheimer's disease. J.Neurochem. 2021 PMID: 33278025
• Gras Lavigne Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP⁺ in a GDNF-dependent manner. ACS Chem.Neurosci. 2021 PMID: 34032411
• Snigdha Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J.Pharmacol.Exp.Ther. 2010 PMID: 19864614

Product Documents for Pimavanserin